Centene Corporation reported strong fourth-quarter 2024 financial results, surpassing Wall Street expectations. The company achieved an adjusted EPS of $0.80, significantly beating the $0.49 estimate, and generated revenue of $40.81 billion, exceeding both the $39.35 billion and $39.13 billion forecasts. Centene also reported a profit of $283 million for the quarter and projected its 2025 adjusted EPS to be above $7.25, slightly above the $7.22 estimate. Meanwhile, Regeneron Pharmaceuticals delivered robust Q4 2024 earnings, driven by strong demand for its eczema drug. The company posted an adjusted EPS of $12.07, surpassing the $11.29 estimate, and revenue of $3.79 billion, exceeding the $3.751 billion estimate. Regeneron also initiated its first-ever quarterly dividend program, declaring a cash dividend of $0.88 per share, and authorized a $3 billion share repurchase program. Regeneron shares rose 3% pre-market following the announcement. Additionally, Cummins reported Q4 2024 revenue of $8.447 billion, beating the $8.071 billion estimate, and a GAAP EPS of $3.02. The company achieved record full-year revenues, net income, EBITDA, and EPS despite challenges in the North American heavy-duty truck market. Cummins projects its FY25 revenue to range from a 2% decline to a 3% increase, with an EBITDA margin between 16.2% and 17.2%. Cummins shares rose 4% pre-market.